Clinical trials: Hepatic Fibrosis
Hepatitis B
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic…
- Trial name
- NCT04971928
- Testing
- GSK3228836
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Hepatic Insufficiency
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
- Trial name
- NCT00968591
- Testing
- Everolimus
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alcoholic Liver Disease
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis
- Trial name
- NCT04557774
- Testing
- Cognitive function test
- Where
- South Korea
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Hepatic Encephalopathy, Cirrhosis
Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)
Hepatic encephalopathy (HE) is a common complication of cirrhosis, which seriously damages the life quality of patients. As the disease progresses, 50-80% of patients with cirrhosis develop HE.
- Trial name
- NCT05140837
- Testing
- Psychometric hepatic encephalopathy score & Stroop test, Drug therapy
- Where
- 31 sites in China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Liver Cirrhosis
Spirulina Tablets Treat Liver Fibrosis/Cirrhosis
Spirulina (Spirulina platensis, SP) is a nutrient-rich blue-green algae that has been widely studied and applied in various health fields.
- Trial name
- NCT06770283
- Testing
- Spirulina tablet
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatic Impairment, Cirrhosis
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
- Conditions
- Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
- Trial name
- NCT05045482
- Testing
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Hepatic Impairment
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh…
- Trial name
- NCT05009680
- Testing
- GB1211
- Where
- 4 sites in Bulgaria
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Hepatic Impairment
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the…
- Trial name
- NCT02581592
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Portal Hypertension, Clinically Significant Portal Hypertension
Assessment of Portal Hypertension With Multiparametric MRI
The purpose of this study is to determine whether new multiparametric magnetic resonance imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR elastography and phase-contrast imaging) can be…
- Trial name
- NCT03436550
- Testing
- mpMRI, ARFI US
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Natural Killer Cell Deficiency, Familial Isolated
Natural Killer (NK) Cells Following Bariatric Surgery
This study will determine the role of the NK cells before and after bariatric surgery. The investigators selected patients with NAFLD. A Fibroscan evaluation will be assessed as a new modality to evaluate liver fibrosis.
- Trial name
- NCT02732535
- Testing
- sleeve gastrectomy , roux-en-y gastric bypass
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Liver Cirrhosis, Hepatic Encephalopathy
Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
The investigators wish to investigate how the Continuous Reaction Time (CRT) method can be used in the diagnosis and monitoring of covert hepatic encephalopathy (cHE)in patients with cirrhosis of the liver.
- Trial name
- NCT01773538
- Testing
- Lactulose and rifaximin, Branched Chain amino acids
- Where
- 2 sites in Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Mette Munk Lauridsen
Visceral Stiffness, Liver Fibrosis
Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse
The acoustic radiation force impulse (ARFI) technology provides real-time measurements of tissue stiffness. Aim: Using the ARFI ultrasonography, the investigators aims are to complete the correlation and validity studies between…
- Trial name
- ARFI (NCT01311934)
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Portal Hypertension, Chronic Liver Disease
EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
This study will directly compare the endoscopic ultrasound guided approach to obtain adequate liver biopsies and portal pressure gradient measurements to the current standard of care which uses the transjugular approach.
- Conditions
- Portal Hypertension, Chronic Liver Disease, Cirrhosis
- Trial name
- NCT05118308
- Testing
- Transjugular hepatic venous pressure gradient measurement with liver biopsy, Endoscopic ultrasound portal pressure gradient measurement with liver biopsy
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre